ANTIPSYCHOTIC DRUG-INDUCED DYSKINESIAS

  • Casey, Daniel, (PI)

Project: Research project

Description

Neuroleptic drugs are highly efficacious antipsychotic agents, but have
several undesirable early and late neurological side effects which are
poorly understood. Reversible acute extrapyramidal syndromes (EPS) of
dystonia or parkinsonism occur in 50% of patients and tardive dyskinesia
(TD), a potentially irreversible syndrome of involuntary movements, mostly
in the orofacial region, may develop in 20% of patients (possibly in 50% of
high risk elderly). Unfortunately, prior to the onset of symptoms cannot
identify who is at risk. The pathophysiology of acute EPS and TD is believed to involve dopamine
(DA) receptor blockade with early EPS due to reduced DA influences and TD
due to overactive DA processes. But little is known about the role of DA
receptor subtypes (D-1, D-2) in these disorders or the mechanisms of how
symptoms develop. Research in a nonhuman primate model with studies that parallel clinical
treatment issues can provide both practical and heuristic data. The proposed studies will evaluated the acute and long-term behavioral
effects of the neuroleptic drug haloperidol (HAL) in 44 Cebus albifrons
monkeys. The central issues are (1) individual vulnerability of each
animal at risk for symptoms; and (2) the time course of developing acute
EPS, DA receptor hypersensitivity, and TD during three separate standard
treatment regimes; (a) periodic, (b) continuous oral, and (c) continuous
depot long-acting treatment. Behavioral changes will be assessed by
perturbations in DA function with DA agonists (apomorphine, amphetamine,
bromocriptine, pergolide, and SKF 38393) and antagonists (haloperidol SCH
23390), before, during, and after HAL. Once acute EPS and TD develop, the long-term outcome and effects of
treatment interventions will be compared with the response of spontaneous
orofacial dyskinesias which have developed in a few geriatric monkeys to
clarify if the idiopathic and drug-induced dyskinesias share a similar
pathophysiology.
StatusFinished
Effective start/end date5/1/8212/31/00

Funding

  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health

Fingerprint

Drug-Induced Dyskinesia
Antipsychotic Agents
Haloperidol
Dyskinesias
Pergolide
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
Dopamine
Bromocriptine
Dopamine Receptors
Apomorphine
Parkinsonian Disorders
Amphetamine
Primates
Hypersensitivity
Serotonin Antagonists
Dystonia
Clozapine
Tardive Dyskinesia
Dopamine Agonists
Cebus

ASJC

  • Medicine(all)